Preclinical study of FASN inhibitors in primary colon cancer cells and in a patient‐derived xenograft model of colorectal cancer also demonstrated potent anti‐tumour activity by suppressing the activation of different oncogenic pathways.32 This evidence concerns the gene FASN and colonic neoplasm.